The Hellenic PH created a new specialized clinical seminar “Time Matters When You Have PH” that was addressed to doctors of the main fields of medicine, pathology, cardiology, pneumology, intensive care, as well as the nursing staff. It is...
For another year we had our annual “Women in Action for PH”, this year our association celebrated 5 years of social work with representatives from all the public bodies, Ph doctors, Ph patients, volunteers, friends, all together we became...
Abstract Background: Vitamin D (Vit D) is linked to various conditions including musculoskeletal, metabolic and cardiopulmonary diseases. However, it is not clear whether correction of vit D deficiency exerts any beneficial effect in patients with pulmonary hypertension. Methods: This...
PH Doctor Stelios Orfanos talks about “Signaling pathways in Pulmonary Arterial Hypertension” PH Doctor Georgios Giannakoulas talks about ” Is there a need to treat more patients earlier?” PH Doctor Olivier Sitbon talks about “Optimizing treatment in patients with...
For the fifth consecutive year, we organized our annual bicycling event in Marousi which proved to be a great success given the participations. This year the town’s Mayor Mr. Patoulis pedaled along and honored us with his presence. On...
The Winter 2015 edition of PHA Europe’s official journal is now online! PHA Europe is very proud of yet another busy and productive year. In the current journal you can find a summary of 2015 activities in a number of areas,...
Eurordis has just released its official video for Rare Disease Day 2016, that will be celebrated on 29th February. Rare diseases are not “rare” at all, since there are more than 6,000 rare diseases. What they all have in common is...
Βy ALISA WOODS, PHD Researchers from Japan described ways to predict the progression and severity of pulmonary hypertension (PAH) in people with left heart disease. Their paper, a review of standard and emerging methods for assessing the lung disease, is titled “The...
BY MARGARIDA AZEVEDO Over the last decade, new oral therapy agents in the form of pills used for the management and treatment of pulmonary arterial hypertension (PAH) have been integrated and improved, such as ERAs, PDE-5 inhibitors, and prostacyclin...
By ANA PAMPLONA, PHD A new study identifies the hemodynamic variables that distinguish patients with idiopathic pulmonary arterial hypertension (PAH) from those with isolated post-capillary pulmonary hypertension (PH), a finding that will help to diagnose and treat more accurately and effectively patients with these...